Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score

Purpose Peginterferon (PEG-IFN) and ribavirin (RBV) combination treatment for patients with chronic hepatitis C (CHC), infected by genotype-1 hepatitis C virus with high viral loads, results in a sustained viral response (SVR) in ~50%. However, a trend of decreasing SVR in the older patients has bee...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology international 2012-10, Vol.6 (4), p.744-752
Hauptverfasser:	Ebinuma, Hirotoshi, Saito, Hidetsugu, Tada, Shinichiro, Nakamoto, Nobuhiro, Ohishi, Tazuko, Tsunematsu, Satoshi, Kumagai, Naoki, Tsuchimoto, Kanji, Tsukada, Nobuhiro, Inagaki, Yasutaka, Horie, Yoshinori, Takahashi, Masahiko, Atsukawa, Kazuhiro, Okamura, Yukishige, Kanai, Takanori, Hibi, Toshifumi
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Body weight Colorectal Surgery Erythrocytes Genotypes Hemoglobin Hepatitis C Hepatitis C virus Hepatology Medicine Medicine & Public Health Original Article Platelets Ribavirin Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose Peginterferon (PEG-IFN) and ribavirin (RBV) combination treatment for patients with chronic hepatitis C (CHC), infected by genotype-1 hepatitis C virus with high viral loads, results in a sustained viral response (SVR) in ~50%. However, a trend of decreasing SVR in the older patients has been reported. In the present study, we verified this trend of treatment efficacy in older patients using the propensity score (PS). Methods We conducted a survey of 327 patients with CHC (genotype 1 and high viral loads) who were treated with PEG-IFN and RBV for 48 weeks. The SVR rate was compared between patients =60 and
ISSN:	1936-0533 1936-0541
DOI:	10.1007/s12072-011-9312-9